Comparative Clinical Study of Oral Tranexamic Acid and Topical Tranexamic Acid with Microneedling in the Management of Melasma

Authors

Thillaikkarasi. A¹, Prasad P.V.S², Kaviarasan.P.K³, Kannambal.K⁴

¹Post Graduate, Department of Dermatology Venereology and Leprosy, Rajah Muthiah Medical College & Hospital, Annamalai University, Chidambaram, India – 608002.
²Professor, Department of Dermatology Venereology and Leprosy, Rajah Muthiah Medical College & Hospital, Annamalai University, Chidambaram, India – 608002.
³Head of the Department, Department of Dermatology Venereology and Leprosy, Rajah Muthiah Medical College & Hospital, Annamalai University, Chidambaram, India – 608002.
⁴Reader, Department of Dermatology Venereology and Leprosy, Rajah Muthiah Medical College & Hospital, Annamalai University, Chidambaram, India – 608002.

Abstract

Background: Melasma is an acquired hyperpigmentary disorder characterised by light to dark-brown macules and patches, particularly affecting the sun-exposed areas. The management of melasma is challenging and requires long term treatment plan. Although various treatment options are available, no mode of treatment guarantees satisfactory results. Recent studies have shown that TXA can prevent UV pigmentation in melasma.

Aim: To compare the efficacy of oral tranexamic acid and topical tranexamic acid with microneedling in patients with melasma in a tertiary care hospital in south India.

Methods: It is a prospective, randomized, open-label study conducted among 60 melasma patients. Patients were divided into two groups, 30 patients were given oral tranexamic acid 250 mg tablet twice daily for three months (Group A) and remaining 30 were treated with topical tranexamic acid with microneedling procedure done at monthly interval for 3 times (Group B), and followed up for three consecutive months. Percentage reduction in baseline Melasma Area and Severity Index (MASI) was assessed at 4-week intervals, and response was recorded.

Results: The mean pre MASI score in group ‘A’ was 13.4 ± 6.92 which is reduced to 3.99 ± 2.05 compared to group ‘B’ where it was 9.96 ± 2.79 and got reduced to 5.21 ± 1.63 after 3 months of treatment The average improvement in MASI score after 12 weeks of treatment for group ‘A’ was 70.29% which was comparatively higher than group ‘B’ in which improvement was only 48.02%.

Conclusions: On the basis of these results, therapeutic response was higher in the oral tranexamic acid group than topical tranexamic acid with microneedling group.

Keywords: Melasma, microneedling, tranexamic acid.

Introduction

Melasma is an acquired pigmented disorder of the skin characterized by light to dark brown macules and patches symmetrically involving the sun-exposed areas of the face, neck and occasionally the forearms.¹ This disease is commonly observed in women of reproductive age.
age with Fitzpatrick skin type IV-VI, rarely in postmenopausal females and males. The etiopathogenesis of melasma is complex. Genetic susceptibility, ultraviolet (UV) light exposure, pregnancy, sex hormones, contraceptive pills, thyroid disease, cosmetics, and phototoxic drugs were implicated in the pathogenesis of melasma. Management of melasma remains a therapeutic challenge, especially in dark skin individuals. Numerous treatment options including topical agents, chemical peels and lasers have been used in the treatment of melasma.

In recent times, some researchers found that tranexamic acid (TXA), a traditional hemostatic drug, has hypopigmentary effect on melasma lesions and also prevents UV-induced pigmentation. The intracellular release of arachidonic acid (AA), a precursor of prostaglandins, and the level of alpha-melanocyte-stimulating hormone increase as a result of plasmin activity. These two substances can activate melanin synthesis. Therefore, the anti-plasmin activity of TXA is thought to be the main mechanism of hypopigmentory effect of this agent.

Materials and Methods
All melasma patients, who were willing to undergo the study and who signed the consent for clinical photograph and study, were selected on the basis of selection criteria. A total number of 60 patents were randomly selected based on selection criteria. Patients were randomised by systematic random sampling into two groups with every odd number patients allotted into group A and even number patients were allotted into group B. Patients in group A received oral tranexamic acid (TXA), group B patients were treated with topical TXA and micro needling.

Inclusion criteria
- Patients with melasma in age group between 18 to 50 years
- All treated cases of melasma with relapse or treatment failure cases (treatment free period should be more than 4 weeks)
- Patients who are willing to give consent to undergo photography, laboratory investigations, willing to take oral TXA and undergo microneedling procedure.

Exclusion criteria
- Age less than 18 years and more than 50 years, unwilling patients
- Patients with unrealistic expectations.
- Pregnancy and lactation.
- Patients with underlying bleeding disorders, cardiovascular diseases, autoimmune disorders, malignancy and long duration of steroid and hormonal therapy.
- Acne and atopic dermatitis patients. History of keloidal tendency and active infections.

Written and informed consent in their own language was obtained from all patients who were selected for the study. A detailed history was taken. Complete heamogram, bleeding and coagulation profile (PT, aPTT, INR), thyroid function test, serum cortisol level, liver and renal function test were carried out in both groups. Melasma Area Severity Index score (MASI) was assessed for all the patients by two different observers. According to MASI score whole face was divided into four areas (A), (forehead (F) 30%, right malar region (RM) 30%, left malar region (LMR) 30% and chin (C) 10%) darkness (D) and homogeneity (H) graded from 0 to 4. The MASI score was calculated by following the equation:

\[
\text{MASI score} = 0.3 \text{ AF} (\text{DF} + \text{HF}) + 0.3 \text{ AMR} (\text{DMR} + \text{HMR}) + 0.3 \text{ AML} (\text{DML} + \text{HML}) + 0.1 \text{ AC} (\text{DC} + \text{HC})
\]
Group A patients (n=30) were treated with oral TXA tablet 250 mg twice daily after food and topical sunscreen with SPF 45 for 3 months duration and group B patients (n=30) were treated with topical TXA with microneedling (1.5 mm) along with topical sunscreen with SPF 45 for 3 months duration.

TXA drug for injection is available as ampoule with 500mg / 5ml. About 4 units of TXA diluted with 96 units of normal saline in a 100 units insulin syringe to get a concentration of 4mg / ml of TXA.

After gentle cleansing, topical anaesthetic gel (Eutectic mixture of lignocaine 2.5 % and prilocaine 2.5%) was applied under occlusion over the treatment area for 45 minutes prior to microneedling. After adequate achievement of topical anaesthesia the lesional skin was stretched and microneedling procedure carried out in vertical, horizontal, and diagonal directions for five times. One ml of TXA solution (4 mg/ml) was applied over 2cm² of lesional area, and the procedure was repeated five times in the above said directions. Ice packs were used before and after the procedure over the melasma areas to minimize the erythema pain and bleeding. The patients were instructed to follow strict photo protective measures. The procedures were repeated three times at monthly intervals (0 (V₁), 4 (V₂), and 8 (V₃) weeks). After the end of third month both groups were advised to continue the sunscreen and advised to come for regular follow up at monthly intervals for the period of three months. Clinical photographs were taken before initiation of therapy and serially during every visit (V) and documented

The MASI score of all patients in both groups were compared and analysed at each visits using ANOVA .Independent sample ‘t’ test was used to assess MASI score between groups.

The detailed MASI score analysis was performed compared within group. The mean value of pre MASI score in group ‘A’ was 13.46 ± 6.92, which further reduced to 3.99 ± 2.05 at the 4th visit (12th week). Likewise the drop in MASI score was
gradual from visit 1 (9.96 ± 2.79) to 4th visit (5.21 ± 1.63) in Group B. The MASI assessment of both groups compared with baseline values showed significant reduction in every visit.

**Fig -1:** MASI Score analysis – within group

**Table -2:** MASI score comparison between groups

<table>
<thead>
<tr>
<th></th>
<th>Mean A</th>
<th>Mean B</th>
<th>‘t’ value</th>
<th>‘P’ Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st Vs 2nd difference</td>
<td>4.79 ± 2.74</td>
<td>2.42 ± 1.08</td>
<td>3.65</td>
<td>.001</td>
</tr>
<tr>
<td>2nd Vs 3rd difference</td>
<td>2.53 ± 1.73</td>
<td>1.29 ± .59</td>
<td>3.07</td>
<td>.004</td>
</tr>
<tr>
<td>3rd Vs 4th difference</td>
<td>2.15 ± 1.47</td>
<td>1.03 ± .39</td>
<td>3.32</td>
<td>.002</td>
</tr>
<tr>
<td>1st Vs. 4th difference</td>
<td>9.47 ± 5.26</td>
<td>4.75 ± 1.36</td>
<td>3.92</td>
<td>.001</td>
</tr>
</tbody>
</table>

Oral TXA treatment group showed 3 fold reduction in MASI compared to baseline value, whereas topical TXA group showed 2 fold reduction from the baseline. Oral TXA is very effective and significantly reduced the melasma pigmentation.

**Fig – 2:** MASI score comparison between groups
Table -3: MASI score improvement in percentages

<table>
<thead>
<tr>
<th>Improvement score grading</th>
<th>MASI 2nd</th>
<th>MASI 3rd</th>
<th>MASI 4th</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>S.D</td>
<td>Mean</td>
</tr>
<tr>
<td>MASI 2nd</td>
<td>34.78</td>
<td>9.40</td>
<td>25.83</td>
</tr>
<tr>
<td>MASI 3rd</td>
<td>54.18</td>
<td>10.15</td>
<td>36.79</td>
</tr>
<tr>
<td>MASI 4th</td>
<td>70.29</td>
<td>7.93</td>
<td>48.02</td>
</tr>
</tbody>
</table>

The MASI score improvement in terms of percentages is presented in the table 17. The average 4th week improvement in group ‘A’ is 34.78 ± 9.40% whereas in group ‘B’ it is 25.83 ± 11.46%. The mean improvement at 8th week is 54.18% in group ‘A’ whereas it us 36.79% in group ‘B’. The 12th week improvement is again comparatively higher for group ‘A’ (70.29) than group B (48.02%).

Fig – 3: MASI score improvement in percentages

Table -4: MASI Score Follow up Comparison

<table>
<thead>
<tr>
<th>VISIT</th>
<th>A</th>
<th>B</th>
<th>‘Z’</th>
<th>‘P’</th>
</tr>
</thead>
<tbody>
<tr>
<td>V₁ 16th week</td>
<td>3.99 ±1.99</td>
<td>5.98±1.49</td>
<td>3.19</td>
<td>.001</td>
</tr>
<tr>
<td>V₂ 20th week</td>
<td>4.85±2.02</td>
<td>6.58±2.11</td>
<td>2.78</td>
<td>.005</td>
</tr>
<tr>
<td>V₃ 24th week</td>
<td>541 ± 2.64</td>
<td>6.88±2.26</td>
<td>2.24</td>
<td>.025</td>
</tr>
</tbody>
</table>

The mean follow up MASI score was comparatively less in group A compared to group B at various weeks of follow up, further the difference being statistically significant. The overall recurrence rate is 56.3%. Recurrence of the disease is observed in 53.6% of group ‘A’ and 60% of group ‘B’ patients.

Fig – 4: MASI score treatment and follow up Comparison
Oral TXA

Before

After

Topical TXA with microneedling

Before

After

Discussion

Melasma, an acquired pigmentary disorder of skin is characterized by hyperpigmented brown to greyish brown macules on the face. The most common locations are the cheeks, upper lips, chin, and forehead, but other sun-exposed areas may also occasionally involved. Melasma is much more common in women during their reproductive years. Melasma may affect any races, it is much more common in darker skin types (skin types IV to VI. The disease prevalence among Asians is about 40% in females and about 20% in males.\(^5\)

The etiopathogenesis of melasma is multifactorial which includes genetic factor, sun exposure, hormonal influence, drugs, cosmetics and stress which play a role in the development of melasma. Therapeutic management of melasma was so far dependent on various combinations of topical, systemic and physical modalities such as lasers and chemical peels. This study focuses on TXA in the management of melasma.

Tranexamic acid prevents the binding of plasminogen to the keratinocytes and thus inhibits UV-induced plasmin activity in keratinocytes. TXA being a plasmin inhibitor depletes the keratinocyte pool of Arachidonic acid (AA) involved in UV-induced melanogenesis.\(^6\)

UVR stimulates the production of angiogenic factors such as VEGF, b-FGF and interleukin-8. VEGF interacts with VEGF receptors present in epidermal keratinocytes which release metabolites of AA and plasminogen from the proliferated vessels, leading to increased melanogenesis. Plasmin plays an important role in the release of VEGF and b-FGF, which are potent melanocyte growth factor, they promote melanocyte
proliferation and increased angiogenesis. TXA reduces VEGF and b-FGF by inhibiting plasmin conversion from plasminogen, hence suppresses neovascularisation and melanogenesis. In treatment of melasma, TXA can be used orally, topically or intradermally by microneedling or microinjections.

Oral TXA was administered to melasma patients in a dose of 250 mg twice daily for 3 to 6 months. The dermal and mixed variants of melasma are highly resistant to treatment, and in such cases TXA may be administered intradermally. Dermaroller used for minimally invasive microneedling treatment increases absorption of the topically applied compounds.

Wu U et al. reported in their study found out significant improvement in the physicians rating scale following oral TXA 250 mg twice daily administration for a period of 6 months for 74 patients, in which 54% had good outcome, 31.1% had fair outcome and 4.1% poor outcome in their study.

Neerja puri et al in their study compared oral TXA Vs triple combination regimen for the treatment of melasma, where they found 64% of MASI score improved in oral TXA group, where as only 56% in triple combination therapy.

Cristina C et al. evaluated the efficacy of the topical with TXA with micro needling in the treatment of melasma. There was significant reduction in MASI score the from baseline. The mean MASI score reduced from 6.35 to 2.87 at 12th week of treatment.

In a study done by Karn D et al. in treatment of melasma, oral TXA found to be relatively safe. They observed oligomenorrhea (14.7%), belching (9.2%) and abdominal cramps (6.9%) as side effects. Hwee Chyen Lee et al. observed that relapse of melasma after stopping TXA 27.2% of those who improved and they suggested another course of TXA or other forms of therapy.

Our study results are comparable with the studies which showed beneficial effects in melasma treatment following oral TXA and topical TXA with microneedling procedure were observed. We observed significant improvement in both modalities of treatment, in which oral TXA shows higher improvement. We observed minimal side effect, but high relapse rate within three months of discontinuation of treatment. This suggests that TXA treatment should be long term, and needs to be maintained for an extended period of time. Further studies are needed to fix optimum duration of treatment for maintenance and prevention of relapse of melasma.

Conclusion
In conclusion, this present study clearly shows that oral TXA has statistically significant clinical improvement of melasma when compared with topical TXA with micro needleling. This study emphazies that tranexamic acid is safe and promising drug in the treatment of melasma. Further research on the long term administration of tranexamic acid and reduction of recurrence rate also is needed.

References


